NuvaRing

NuvaRing. It is a form of combined hormonal contraception that is inserted into the vagina and releases hormones to prevent pregnancy. The device is a flexible, transparent polymer ring that steadily delivers etonogestrel and ethinylestradiol over a three-week period. It offers a convenient, user-controlled alternative to daily oral contraceptive pills and longer-acting methods like the intrauterine device.

Description and mechanism of action

The device is a flexible, transparent ring approximately 54 mm in diameter, made of ethylene vinylacetate copolymers. It functions by continuously releasing the progestogen etonogestrel, the active metabolite of desogestrel, and the estrogen ethinylestradiol directly through the vaginal mucosa into the systemic circulation. This steady delivery suppresses the gonadotropin-releasing hormones from the hypothalamus, which in turn inhibits the pituitary gland's secretion of follicle-stimulating hormone and luteinizing hormone. The primary mechanism of action is the suppression of ovulation, alongside thickening of the cervical mucus to impede sperm transport and creating endometrial changes unfavorable for implantation.

Indications and usage

The primary indication is for the prevention of pregnancy in women of reproductive age. It is inserted into the vagina by the user, where it remains for three consecutive weeks, followed by a one-week ring-free interval during which a withdrawal bleed typically occurs. A new ring is inserted after this week, maintaining a continuous four-week cycle. It may also be used in extended or continuous regimens, as directed by a healthcare provider, to manage conditions like endometriosis or heavy menstrual bleeding, though these are off-label uses. Correct and consistent use, as with all contraceptives, is required for optimal effectiveness.

Contraindications and side effects

Contraindications are similar to other combined oral contraceptive pills and include a history of venous thromboembolism, arterial thrombosis, severe hypertension, migraine with aura, diabetes mellitus with vascular complications, liver disease, and known or suspected breast cancer. Common side effects can include vaginitis, headache, nausea, breast tenderness, and mood changes. As with all estrogen-containing contraceptives, there is an increased risk of serious adverse events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, particularly in women with additional risk factors like smoking and advanced age.

Clinical trials and efficacy

Clinical trials conducted by Organon International, the original developer, demonstrated high efficacy and user satisfaction. With perfect use, the Pearl Index is approximately 0.3-0.6, indicating less than one pregnancy per 100 women-years of use. Typical use failure rates are higher, around 9%, largely due to incorrect or inconsistent use. Studies published in journals like *Contraception* and *Fertility and Sterility* have shown its efficacy to be comparable to combined oral contraceptives. Research has also investigated its pharmacokinetic profile and its effects on hemostasis and lipid metabolism.

History and development

The concept was developed by Organon International in the Netherlands. The research and development leveraged existing knowledge from oral contraceptives and aimed to create a novel delivery system that could improve compliance. It received approval from the European Medicines Agency in 2001 and was subsequently approved by the Food and Drug Administration for use in the United States in 2001. The technology represented a significant innovation in the field of women's health, providing a new option in the contraceptive market dominated by Bayer and Pfizer.

Regulatory status and availability

Following initial approvals, it became widely available by prescription in many countries across North America, Europe, and Latin America. In the United States, it is marketed by Merck & Co., which acquired Schering-Plough, the subsequent owner of Organon. Its regulatory status is that of a prescription-only medicine. Availability and cost can vary significantly by country and healthcare system, and it is often covered under insurance plans and national health services like the National Health Service in the United Kingdom. Generic versions have also entered the market following patent expirations.